| DACRIN | DACRIN 2020-7: A survey study to assess the individual, team-level and organisational research capacity of government and non-government (NGO) services in the NSW alcohol and other drugs (AOD) sector | Sterling, Hudson et al. 2023 |
| DACRIN | DACRIN 2020-6: The 'DACRIN Data Project': a consensus approach to harmonising data collection for AOD services. | Monds, Topp at al. 2023 |
|
DACRIN
(SESLHD)
| DACRIN 2020-1: The role of mental health and cognitive functioning in predicting successful completion of the magistrates early referral in to treatment (MERIT) program |
Link to publication coming soon |
|
DACRIN
(SESLHD)
| DACRIN 2019-5: A pilot study integrating a contraception clinic into an Australian inner-city drug and alcohol service | Day, White et al. 2020
|
|
DACRIN
(SLHD)
| DACRIN 2019-1: Drug and alcohol services for the Lebanese Muslim community in Sydney (1800 Relief) |
Lindegaard Moensted and Day 2022
|
|
NDARC
| DACRIN 2018-6: An open label, multicentre, single arm trials of monthly injections of depot buprenorphine in people with opioid dependence (CoLAB) |
Farrell, Shahbazi et al. 2022
|
|
DACRIN
(SESLHD)
| DACRIN 2018-5: Implementation and evaluation of take-home naloxone for opioid overdose prevention in emergency department settings. The ONE study |
Black, Monds et al. 2022
|
|
DACRIN
(SESLHD)
| DACRIN 2018-4: HS-17-585 A randomised, open-label, multi-centre trial comparing a once-weekly and once-monthly long-acting subcutaneous injectable depot of buprenorphine to buprenorphine standard of care in adult outpatients with opioid dependence (DEBUT) |
Lintzeris, Dunlop et al. 2021
|
|
Turning Point
| DACRIN 2018-4 (DEBUT sub-study): Patient experiences of long-acting subcutaneous injectable depot buprenorphine: a qualitative study. |
Barnett, Savic et al. 2021
|
| DACRIN (SESLHD) | DACRIN 2018-2: Obtaining normative substance use, health and wellbeing data for clients attending NSW public drug and alcohol treatment services (ATOP Normative) |
Lintzeris, Deacon et al. 2021 |
|
DACRIN
(HNELHD)
| DACRIN 2018-1: Assessing the safety and feasibility of long-acting depot of buprenorphine in adults requiring treatment for opioid use disorder in NSW custodial settings (UNLOC-T) |
Roberts, White et al. 2021
Dunlop, White et al. 2022
Ling, White et al. 2022
Little, White et al. 2023
|
| DACRIN (HNELHD) | Incentives to Quit tobacco in Pregnancy (iQuiP) | Jackson et al., 2023 |
| The Kirby Institute | DACRIN 2017-3: Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) |
Yee, Carson et al. 2022 |
|
DACRIN
(SLHD)
| DACRIN 2017-2: Improving management of comorbid substance use and mental illness with an integrated stepped care approach. Pathways to comorbidity care |
Louie, Giannopoulos et al. 2021
Louie, Morley et al. 2021
|
|
DACRIN
(SESLHD)
| DACRIN 2017-1: Implementation and evaluation of take-home naloxone for opioid overdose prevention in drug and alcohol treatment and needle syringe programs attendees (ORTHN Naloxone_TRGS) |
Lintzeris, Monds et al. 2020
Monds, Bravo et al. 2022
|
| DACRIN (SLHD) | DACRIN 2016-4: Defining the clinical role of topiramate in the treatment of alcohol dependence in Australia (Topiramate for alcohol dependence) | Morley, Kranzler et al. 2018 Morley, Kranzler et al. 2024 |
|
DACRIN
(SESLHD)
| DACRIN 2016-2: Clinical Outcomes and Quality Indicators (COQI) framework evaluation: Establishing the psychometric properties and developing a composite indicator for the NSW DAS COQI Framework. | COQI Program |
| The Kirby Institute | DACRIN 2016-1: Scale up of treatment for hepatitis C infection among people who inject drugs: A phase IV, open-label, single arm, multicentre trial of elbasvir/grazoprevir for genotype 1 or 4 in people with chronic hepatitis C virus infection and recent injecting drug use or receiving opioid substitution therapy (DARLO C) |
Grebely, Read et al. 2020 |
|
DACRIN
(SESLHD)
| DACRIN 2015-3: HS-14-499 An open-label multicentre study assessing the long-term safety of a once-weekly and once-monthly, long-acting subcutaneous injection depot of buprenorphine in adult outpatients with opioid use disorder |
Frost, Bailey et al. 2019
|
|
DACRIN
(SESLHD)
| DACRIN 2015-1: An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients (Sativex 2) |
Lintzeris, Bhardwaj et al. 2019
|
|
DACRIN
(HNELHD)
| DACRIN 2014-1: Kronic in the clinic 2.0 (KIT-C): The use of synthetic cannabinoids by NSW cannabis clinic clients. |
Jackson, Brown et al. 2021
|
| The Kirby Institute | DACRIN 2012-1: Healthy liver campaign (LiveRLife) |
Marshall, Micallef et al. 2015
|